Two New Bills Present Challenges to DNA Patentability
This time the challenge to the patents, commonly called gene patents, comes from the US House of Representatives in the form of two bills introduced on March 15 by Rep. Lynn Rivers (D-Mich.). If enacted, each of these would threaten future biotech innovation in the US.
Biotech industry’s still waiting to break out
It turns out that even with the genome in hand, discovering drugs and testing them to prove they work is an expensive, grueling process.
Rating the Nation’s Best and Worst Jobs
According to this year’s edition of “Jobs Rated Almanac” the nation’s single best job in terms of low stress, high compensation, lots of autonomy, tremendous hiring demand and several other key criteria, is biologist.
Battling Hunger With Biotechnology
Biotech Can Be Useful Development Tool, Scientists Say
Motorola shedding biochip biz
Motorola Inc. has put its life sciences business up for sale in a move that is dashing CEO Christopher Galvin’s dream of making biochips the company’s next big success.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments